SpringWorks Therapeutics SWTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
SpringWorks Therapeutics (SWTX) Business Model and Operations Summary
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Key Insights
SpringWorks Therapeutics (SWTX) Core Market Data and Business Metrics
Latest Closing Price
$41.88Market Cap
$3.15 BillionPrice-Earnings Ratio
-12.03Total Outstanding Shares
74.94 Million SharesTotal Employees
368Dividend
No dividendIPO Date
September 13, 2019SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
100 Washington Boulevard, Stamford, CT, 06902
Historical Stock Splits
If you bought 5 shares of SWTX before March 17, 2011, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| March 17, 2011 | 1-for-5 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $4.76 Million |
| Net Cash Flow, Continuing | $-106.29 Million |
| Net Cash Flow From Investing Activities, Continuing | $64.55 Million |
| Net Cash Flow From Operating Activities | $-175.60 Million |
| Net Cash Flow From Operating Activities, Continuing | $-175.60 Million |
| Net Cash Flow From Investing Activities | $64.55 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $74.13 Million |
| Net Income/Loss Attributable To Parent | $-258.13 Million |
| Diluted Earnings Per Share | $-3.48 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Nonoperating Income/Loss | $26 Million |
| Income/Loss Before Equity Method Investments | $-272.13 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-259.02 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-887,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-259.02 Million |
| Other Comprehensive Income/Loss | $-259.02 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $481.10 Million |
| Noncurrent Liabilities | $6.18 Million |
| Assets | $587.28 Million |
| Inventory | $10.21 Million |
| Equity | $481.10 Million |
| Wages | $31.22 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||